Verrica Pharmaceuticals Inc. (VRCA)
| Market Cap | 43.75M |
| Revenue (ttm) | 7.57M |
| Net Income (ttm) | -76.58M |
| Shares Out | 91.78M |
| EPS (ttm) | -1.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 663,803 |
| Open | 0.518 |
| Previous Close | 0.522 |
| Day's Range | 0.463 - 0.548 |
| 52-Week Range | 0.463 - 11.410 |
| Beta | 1.45 |
| Analysts | Hold |
| Price Target | 6.00 (+1,158.65%) |
| Earnings Date | Mar 11, 2025 |
About VRCA
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which include... [Read more]
Financial Performance
In 2024, Verrica Pharmaceuticals's revenue was $7.57 million, an increase of 47.66% compared to the previous year's $5.12 million. Losses were -$76.58 million, 14.3% more than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for VRCA stock is "Hold." The 12-month stock price forecast is $6.0, which is an increase of 1,158.65% from the latest price.
News
Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants John Fraunces - Director, Corporate Communications, LifeSci Advisors, IR Ja...
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4'24 concurrent with significantly lower operating expenses –
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disea...
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...
Verrica Announces Pricing of $42.0 Million Public Offering
WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...
Verrica Announces Proposed Public Offering
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...
Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
SAN FRANCISCO , Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. investors that the firm is investigating potential legal claims relating to the compan...
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance -
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermato...
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
NEW ORLEANS , Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disea...
Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Kevin Gardner - Managing Director, LifeSci Advisors Ted White - President ...
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Reports YCANTH ® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor –
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesion...
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and i...
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disease...
Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Chris Calabrese - MD, LifeSci Advisors Ted White - President & CEO Joe Bonacc...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Prelimina...
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disease...
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disease...